These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 9162395)

  • 1. [The vasomotor effects of the enzymes of the fibrinolytic system in rats].
    Sergeev IIu; Bashkov GV
    Fiziol Zh Im I M Sechenova; 1996; 82(10-11):52-7. PubMed ID: 9162395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergism of tissue-type plasminogen activator (t-PA) and single-chain urokinase-type plasminogen activator (scu-PA) on clot lysis in vitro and a mechanism for this effect.
    Gurewich V; Pannell R
    Thromb Haemost; 1987 Jun; 57(3):372-3. PubMed ID: 3116707
    [No Abstract]   [Full Text] [Related]  

  • 3. Cleavage of surfactant-incorporating fibrin by different fibrinolytic agents. Kinetics of lysis and rescue of surface activity.
    Günther A; Markart P; Kalinowski M; Ruppert C; Grimminger F; Seeger W
    Am J Respir Cell Mol Biol; 1999 Dec; 21(6):738-45. PubMed ID: 10572071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Changes in the components of the animal fibrinolytic system induced by the action of physiological activators and enzymes of fungal origin].
    Andreenko GV; Serebriakova TN; Shimonaeva EE; Liutova LV; Karabasova MA
    Nauchnye Doki Vyss Shkoly Biol Nauki; 1983; (3):51-4. PubMed ID: 6342687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Structure, function and use of fibrinolysis-promoting and inhibiting factors].
    Bachmann F
    Arzneimittelforschung; 1988 Mar; 38(3A):474-8. PubMed ID: 3134901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complementary modes of action of tissue-type plasminogen activator and pro-urokinase by which their synergistic effect on clot lysis may be explained.
    Pannell R; Black J; Gurewich V
    J Clin Invest; 1988 Mar; 81(3):853-9. PubMed ID: 2963831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serine-proteases as plasminogen activators in terms of fibrinolysis.
    Flemmig M; Melzig MF
    J Pharm Pharmacol; 2012 Aug; 64(8):1025-39. PubMed ID: 22775207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Features of the effect of tissue and urokinase-type plasminogen activators on vascular tone].
    Sergeev IIu
    Dokl Akad Nauk; 1997 Oct; 356(4):555-7. PubMed ID: 9424175
    [No Abstract]   [Full Text] [Related]  

  • 9. Activation of the fibrinolytic system.
    Robison AK; Collen D
    Cardiol Clin; 1987 Feb; 5(1):13-9. PubMed ID: 3103919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
    Matsuo O; Rijken DC; Collen D
    Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasmin induces local thrombolysis without causing hemorrhage: a comparison with tissue plasminogen activator in the rabbit.
    Marder VJ; Landskroner K; Novokhatny V; Zimmerman TP; Kong M; Kanouse JJ; Jesmok G
    Thromb Haemost; 2001 Sep; 86(3):739-45. PubMed ID: 11583303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Thrombolysis using tissue-type plasminogen activator and pro-urokinase: synergism; mutants and hybrids].
    Páramo JA; Fernández FJ; Cuesta B; Paloma MJ; Rocha E
    Sangre (Barc); 1989 Aug; 34(4):297-9. PubMed ID: 2505395
    [No Abstract]   [Full Text] [Related]  

  • 13. [Tissue plasminogen activator].
    Matsuo O
    Rinsho Ketsueki; 1984 Jul; 25(7):1004-10. PubMed ID: 6542154
    [No Abstract]   [Full Text] [Related]  

  • 14. Characterization and antithrombotic action of tissue plasminogen activator.
    Bergqvist D; Nilsson IM; Pandolfi M
    Experientia; 1984 Jan; 40(1):67-8. PubMed ID: 6229416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluorogenic fibrinogen and fibrin facilitate macromolecular assembly and dynamic assay of picomolar levels of plasminogen activators under well mixed conditions.
    Wu JH; Diamond SL
    Thromb Haemost; 1995 Aug; 74(2):711-7. PubMed ID: 8585011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platelet-dependent thrombin generation after in vitro fibrinolytic treatment.
    Aronson DL; Chang P; Kessler CM
    Circulation; 1992 May; 85(5):1706-12. PubMed ID: 1533349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Molecular mechanisms of fibrinolysis and perspectives of thrombolytic therapy].
    Veremeenko KN; Kizim AI
    Vopr Med Khim; 1984; 30(5):13-22. PubMed ID: 6084892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The nature of synergy between tissue-type and single chain urokinase-type plasminogen activators.
    Fry ET; Mack DL; Sobel BE
    Thromb Haemost; 1989 Nov; 62(3):909-16. PubMed ID: 2512679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potentiation by heparin fragment CY 222 (Choay) of thrombolysis induced by human tissue-type plasminogen activator.
    Juhan-Vague I; Stassen JM; Alessi MC; Elias A; Aillaud MF; Serradimigni A; Collen D
    Semin Thromb Hemost; 1989 Oct; 15(4):390-4. PubMed ID: 2554499
    [No Abstract]   [Full Text] [Related]  

  • 20. Fibrinolytic agents: mechanisms of activity and pharmacology.
    Lijnen HR; Collen D
    Thromb Haemost; 1995 Jul; 74(1):387-90. PubMed ID: 8578491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.